Correction to: RE‑MIND2: comparative effectiveness of tafasitamab plus lenalidomide versus polatuzumab vedotin/bendamustine/rituximab (pola‑BR), CAR‑T therapies, and lenalidomide/rituximab (R2) based on real‑world data in patients with relapsed/refractory diffuse large B‑cell lymphoma.

Authors :: Nowakowski GS
Yoon DH
Mondello P
Joffe E
Peters A
Fleury I
Greil R
Ku M
Marks R
Kim K
Zinzani PL
Trotman J
Sabatelli L
Waltl EE
Winderlich M
Sporchia A
Kurukulasuriya NC
Cordoba R
Hess G
Salles G
Source :: Annals of hematology [Ann Hematol] 2023 Sep; Vol. 102 (9), pp. 2643-2644.
Publication Year :: 2023

Full Text Access

Tools